<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015859</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol IGxD04</org_study_id>
    <nct_id>NCT01015859</nct_id>
  </id_info>
  <brief_title>Spontaneous Atrioventricular Conduction Preservation</brief_title>
  <acronym>CAN-SAVER</acronym>
  <official_title>A Prospective Canadian Multi-center Randomized Study of the Benefits of Spontaneous Atrioventricular Conduction (Can Save R)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sorin Group Canada</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to assess the clinical benefits resulting from SafeR by comparison
      with standard dual chamber programming (DDD) with a long atrioventricular (AV) delay.

      The benefits will be assessed by comparing the percentage of ventricular pacing, the
      incidence of atrial arrhythmias, and the evolution of the hemodynamic status as observed
      through echo parameter and atrial natriuretic peptide/brain natriuretic peptide (ANP/BNP)
      measurements.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the effectiveness of SafeR</measure>
    <time_frame>1 and 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>preserve natural AV conduction compared to DDD Long AVD</measure>
    <time_frame>1 and 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>demonstrate the effectiveness of SafeR to reduce AF incidence on a LT basis</measure>
    <time_frame>1 and 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>compare the effects of SafeR vs DDD Long AVD on LV function</measure>
    <time_frame>1 and 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>total mortality</measure>
    <time_frame>1 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHF-related mortality &amp; hospitalisations</measure>
    <time_frame>1 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of systemic BP</measure>
    <time_frame>1 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF-related AEs</measure>
    <time_frame>1 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of cardiac asynchrony [interventricular (RV-LV) &amp; intraventricular (4 segments)</measure>
    <time_frame>1 and 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Patients With Pacemaker With Conduction Problems</condition>
  <arm_group>
    <arm_group_label>DDD long AV delay</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pacemaker is programmed in DDD mode with long AV delay (250 msec)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AAI SafeR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pacemaker is programmed in AAI SafeR mode</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacing mode</intervention_name>
    <description>To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing</description>
    <arm_group_label>AAI SafeR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient who fulfils one or more of the official guidelines to be implanted with a
             dual-chamber pacemaker (primo-implantation3) may be included in the study.

        Exclusion Criteria:

        The patients presenting with one or more of the following characteristics cannot be
        included:

        Permanent complete AV block

          -  Permanent atrial and/or ventricular arrhythmias

          -  already implanted with a cardioverter-defibrillator (ICD)

          -  Likely to have a cardiac surgery in the next six months, mainly for:

          -  severe coronary artery disease

          -  severe valvular disease

          -  AV node ablation

          -  Refuses to sign an consent form after having received the appropriate information

          -  Refuses to co-operate

          -  Not able to understand the study objectives and protocol

          -  Not available for scheduled follow-up

          -  With a life expectancy less than one year

          -  Already included into another clinical study competing with the objectives of the
             CAN-SAVE R study

          -  &lt;18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Thibault, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute, Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grey Nuns Hospital, Edmonton</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 5X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Hospital, Queens University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Hospital</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôtel-Dieu de St Jérome</name>
      <address>
        <city>St Jérome</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier régional de Trois-Rivières</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital, Saskatoon</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montreal Heart Institute</investigator_affiliation>
    <investigator_full_name>Bernard Thibault</investigator_full_name>
    <investigator_title>Cardiologist</investigator_title>
  </responsible_party>
  <keyword>AV conduction</keyword>
  <keyword>Atrial fibrillation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

